Texas A&M System and GlaxoSmithKline receive U.S. Government approval to
establish influenza vaccine facility in Texas
Team will develop and manufacture GSK's next generation influenza vaccines to
protect the nation against global pandemics
AUSTIN, Texas and PHILADELPHIA, March 26, 2013
AUSTIN, Texas and PHILADELPHIA, March 26, 2013 /PRNewswire/ --GlaxoSmithKline
plc (GSK) and The Texas A&M University System announced today that the U.S.
Department of Health and Human Services (DHHS) has approved the establishment
of a $91 million influenza-vaccines manufacturing facility as the anchor of
the Center for Innovation in Advanced Development and Manufacturing (CIADM) in
Bryan-College Station, Texas.
The announcement was hosted by Governor Rick Perry at the Texas State Capitol,
and was attended by a number of dignitaries including Texas A&M System
Chancellor John Sharp, Dr. Robin Robinson, DHHS Deputy Assistant Secretary and
Director of the Biomedical Advanced Research and Development Authority
(BARDA), and Antoon Loomans, Senior Vice President, GSK Vaccines.
"Today's announcement is a huge win for Texas and for the nation," Governor
Perry said. "The Texas A&M Center, anchored by this facility, is expected to
bring more than $41 billion in expenditures within the State of Texas over the
next 25 years, and will add more than 6,800 direct and related jobs to
The TAMUS influenza vaccines manufacturing center will afford GSK the
capabilities to eventually manufacture influenza vaccine based on a
proprietary cell-culture line, EB66®. Most existing influenza vaccine is
manufactured using fertilized chicken eggs. The cell-culture process will
supplement the vaccine supply from eggs, and facilitate a rapid national
vaccine response in the event of a pandemic.
GSK Vaccines produces 30 vaccines worldwide, eleven of which are licensed by
the FDA. The Texas A&M-GSK venture will complement and support the company's
existing influenza vaccines operations, based in Quebec, Canada, and Dresden,
Germany. GSK's operations hub in Marietta, Pennsylvania will package, inspect
and distribute influenza vaccine manufactured at the Texas A&M Center. In
2012, GSK provided more than 20 million flu shots for the U.S. market and
recently became the first major U.S. vaccines provider to gain FDA-approval
for a broader-protection, four-strain (quadrivalent) influenza vaccine shot
that will be available in time for the 2013-14 flu season.
"GSK is privileged to deepen our commitment to U.S. public health, as part of
this unprecedented public-private collaboration to protect against pandemics
and bio-threats," noted Loomans. "In Texas A&M we have found a partner with a
rich tradition of service, and with pioneering technologies that will benefit
the entire pharmaceutical industry in making vaccines available and accessible
to all in need."
One of only three CIADMs to be developed in the U.S., the Texas A&M Center is
at the vanguard of U.S. pandemic-preparedness efforts and represents
unprecedented public-health collaboration among state and federal governments,
academia and private industry. Once constructed and operational, the Center's
influenza manufacturing facilitywill be able to supply 50 million doses of
pandemic influenza vaccine within four months of an outbreak. BARDA conceived
the public-private formula to assure a strong biosecurity product development
and manufacturing base on U.S. soil, ensuring that the nation would have rapid
access to vaccines and therapeutics in the advent of influenza pandemics, or
chemical, biological, radiological, and nuclear attacks.
"We are honored to welcome GSK to Texas A&M as a key partner in the Center for
Innovation," said Sharp."GSK's dedication to public service is well-aligned
with the Texas A&M tradition of serving the nation and defining its future
through research and scholarship. Equally important is the cultural and
philosophical match between GSK and the A&M System, as reflected by GSK's
desire to collaborate with academia and the U.S. government, and their ongoing
commitment to helping address global health scourges such as pandemic
influenza and malaria."
The Texas A&M Center for Innovation is led by Dr. Brett Giroir, Vice
Chancellor for Strategic Initiatives at the Texas A&M System, and a core team
of A&M experts in biotechnology, infectious diseases, facilities planning and
construction, federal acquisitions/contracting, and government affairs. The
partnership with GSK was founded on a long, collaborative relationship between
Texas A&M and the Wallonia Region of Belgium, with specific planning for this
project beginning in the spring of 2010.
"GSK's decision to partner with Texas A&M and bring their vaccine
manufacturing to our state is a testament to the investments that the A&M
System and the State of Texas have made in the people, infrastructure and
technologies, much of which came from critical state programs such as the
Emerging Technology Fund," Giroir said. "GSK brings unequaled influenza
vaccine development, manufacturing, and regulatory expertise to our Center.
Equally important, GSK brings its cell based influenza vaccine development
program, which we have assessed to be the most promising near term influenza
vaccine technology to improve upon current egg based vaccines."
The Texas A&M Center for Innovation represents the largest commitment of a
global biopharmaceutical company to partner within Texas, and will be an
important catalyst to the future growth of this industry within the State.
U.S. Government Funding
Efforts highlighted in this release have been funded in whole or in part with
Federal Funds from the DHHS/ASPR/BARDA, under contract numbers
HHSO100200600011C, HHSO100200700029C and HHSO100201200002I.
About the A&M System
The A&M System is one of the largest systems of higher education in the
nation, with a budget of $3.5 billion. Through a statewide network of 11
universities, seven state agencies and a comprehensive health science center,
the A&M System educates more than 120,000 students and makes more than 22
million additional educational contacts through service and outreach programs
each year. Externally funded research expenditures exceed $780 million and
help drive the state's economy.
Steven B. Moore
Texas A&M University System
About the Texas A&M Center for Innovation
The Texas A&M Center for Innovation in Advance Development and Manufacturing
(CIADM) is one of three centers established in June, 2012 by the US Department
of Health and Human Services to enhance the nation's emergency preparedness
against emerging infectious diseases, including pandemic influenza, and
chemical, biological, radiological and nuclear threats. The Center is founded
on an initial $285.6 million investment, including a $176.6 million
contribution from the US Department of Health and Human Services, with the
remainder cost-shared by commercial and academic proposal partners.
The Center will perform research and advanced development to accelerate
vaccines and other medical products through pre-clinical and clinical
development and produce these products in cases of pandemics or other national
emergencies. Through these activities, the Center will address a recognized
shortcoming in preparedness and response to known and unknown threats, and
will improve our nation's ability to protect the health of its citizens in
With GSK and other partners, TAMUS also will utilize CIADM capabilities to
develop and transition platform technologies to accelerate new treatments for
conditions as diverse as cancer and cardiovascular disease.
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and
healthcare companies – is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For further
information please visit http://us.gsk.com/
 *EB66® exclusively licensed from Vivalis by GSK Biologicals S.A. for the
field of Influenza and sublicensed use at the Texas A&M Center for Innovation
in Advanced Development and Manufacturing (CIADM).
Contact: Media, Rob Perry, +1-407-492-4616, Philadelphia; or Sarah Alspach,
+1-202-715-1048; Investors, Sally Feguson, +44-0-20-8047-5543, London; or Lucy
Budd, +44-0-20-8047-2248, London; or Tom Curry, +1-215-751-5419, Philadelphia;
or Gary Davies, +44-0-20-8047-5503, London; or James Dodwell,
+44-0-20-8047-2406, London; or Jeff McLaughlin, +1-215-751-7002, Philadelphia;
or Ziba Shamsi, +44-0-20-8047-3289, London
Press spacebar to pause and continue. Press esc to stop.